Search Results 371-380 of 18366 for alopecia

  1. Clinical trials - Oncology (Medical)

    Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...

  2. Head and neck cancers - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Vulvar skin disorder, Breast skin change, Rosacea, Pigmentation disorder ...

  3. Head and neck cancers - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Vulvar skin disorder, Breast skin change, Rosacea, Pigmentation disorder ...

  4. Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working - Mayo Clinic

    (which must be ≤ grade 2), alopecia and/or endocrinopathies related to prior immunotherapy which are controlled with hormone replacement. - Patients must ...

  5. Testing the Addition of an Anti-cancer Drug, ASTX727, to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

    - Patients who have recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia.

  6. A Study of ONO-7475 in Patients With Acute Leukemias - Mayo Clinic

    Patients not recovered to Grade 1 or stabilized from the effects (excluding alopecia) of any prior therapy for their malignancies. Concurrent treatment with ...

  7. Head and neck cancers - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Seborrheic dermatitis, Melasma, Vitiligo. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann ...

  8. Head and neck cancers - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

  9. Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer - Mayo Clinic

    Experienced resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If patient underwent major surgery or ...

  10. Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma - Mayo Clinic

    All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4 grade =< 1 (except alopecia); certain ...